New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
Sep 21, 2020
0
4
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care—bortezomib, ...
May 29, 2020
0
2
Patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma now have a new treatment option—a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The U.S. Food ...
Apr 29, 2020
0
1
A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled ...
Feb 27, 2020
0
0
Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the U.S. ...
Dec 4, 2019
0
1
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and ...
Sep 17, 2019
0
0
Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according ...
Sep 9, 2019
0
1
Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular ...
Jun 26, 2019
0
0
Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin-receptor-2 ...
Jun 25, 2019
0
0
A new pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer. Based on these promising results ...
Jun 10, 2019
0
1
